Catalent Expands Softgel Capacity with Accucaps Acquisition
PTSM: Pharmaceutical Technology Sourcing and Management
Catalent adds two softgel facilities and packaging capabilities with acquisition of Canada-based Accucaps.
Catalent announced on Nov. 28, 2016 that it has agreed to acquire Accucaps Industries Limited, a Canada-based developer and manufacturer of over-the-counter, high potency, and conventional pharmaceutical softgels.
Upon completion of the acquisition, Accucaps’ more than 500 employees at its two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 softgel technologies facilities. The Accucaps facilities house sizeable blistering, bottling, and other packaging capabilities, as well as high-potency prescription softgel development and manufacturing expertise that are complementary to Catalent’s, the company reports.
“Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments,” said Aris Gennadios, Catalent’s President of Softgel Technologies, in a press statement.
Financial details of the transaction have not been disclosed. The acquisition is subject to Canadian governmental approval.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
